5G-EMERALD: Amivantamab in Malignant Brain Tumours — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

5G-EMERALD: Amivantamab in Malignant Brain Tumours — Stella

Home/Malignant Primary Gliomas/

View on ClinicalTrials.gov

Recruiting

Back to Malignant Primary Gliomas trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United Kingdom

Cambridge University Hospitals, Cambridge

The Royal Marsden Hospital - Drug Development Unit, Sutton

Key details

Phase

Early testing

Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust

Enrollment target

~12 participants

Started

October 2024

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

16 Years and older

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.